Adagene (ADAG) vs BGM Group (BGM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Adagene (ADAG) has outperformed BGM Group (BGM) over the past year, losing 2.2% versus a loss of 96.7%. Over five years, ADAG leads with a -79.7% price change compared with -98.3% for BGM. Adagene is the larger company by market cap ($118.2 million vs $108.6 million), about 1.1 times the size.
BGM Group converts more of its revenue into profit, with a net margin of -52.6% versus -229.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | BGM |
|---|---|---|
| Share price | $1.76 | $8.13 |
| Market cap | $118.17M | $108.57M |
| 1-day change | -12.44% | 0.00% |
| YTD return | -6.88% | -92.77% |
| 1-year return | -2.22% | -96.73% |
| 5-year return | -79.75% | -98.31% |
| EPS (TTM) | $-0.37 | $-4.80 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | $37.92M |
| Revenue growth (YoY) | +7332.76% | +51.09% |
| Net income (latest FY) | $-17.61M | $-19.94M |
| Gross margin | — | 16.64% |
| Operating margin | -279.48% | -33.18% |
| Net margin | -229.56% | -52.59% |
| 52-week high | $4.85 | $263.70 |
| 52-week low | $1.27 | $0.00 |
| Distance from 52-week high | -63.71% | -96.92% |
| Analyst consensus | none | — |
| Avg. price target upside | +463.07% | — |
| Average volume | 348.81K | 6.18K |
| Shares outstanding | 67.14M | 12.69M |
| Employees | 128 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ADAG has outperformed BGM by 94.5 percentage points over the past year.
- BGM Group is more profitable, keeping -52.6 cents of every revenue dollar as net income versus -229.6 cents for Adagene.
- Adagene grew revenue faster in its latest fiscal year (+7332.76% vs +51.09%).
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
ADAG vs BGM FAQ
Which is bigger, Adagene or BGM Group?
Adagene (ADAG) is larger, with a market capitalization of $118.17M compared with $108.57M for BGM Group (BGM).
Which stock has performed better over the past year, ADAG or BGM?
ADAG returned -2.22% over the past 12 months, compared with -96.73% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and BGM Group in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.